September 23, 2025
Photo Credit: Thinkstock
SYDNEY — The International Myopia Institute (IMI) has published its latest white paper, IMI—Interventions for Controlling Myopia Onset and Progression 2025, in Investigative Ophthalmology & Visual Science (IOVS).
The paper addresses one of the most pressing global eye health issues: the rising prevalence of myopia, particularly in East and Southeast Asia, and the urgent need for effective strategies to slow its progression and delay onset.
Building on the landmark 2019 IMI review, this updated white paper examines the evidence for interventions across five categories:
- Optical (e.g., specially designed spectacles and contact lenses),
- Pharmacological (including low-dose atropine),
- Environmental/behavioral (such as increasing outdoor time),
- Colored light approaches, and
- Surgical methods (currently at experimental stages).
Only randomized controlled trials were included in assessing established interventions, ensuring the report is evidence-based and clinically relevant. For newer and emerging treatments, the paper highlights both promise and the gaps that require further study.
“There are now multiple effective interventions available across most categories, giving clinicians real tools to manage myopia proactively. At the same time, this white paper underscores the need for further research to understand why myopia control treatments work, so we can refine and expand treatment options for the future,” said Professor Mark Bullimore, Chair of the IMI white paper.
The 2025 interventions review confirms:
- Safe and effective treatments exist today, especially optical and pharmacological options.
- Environmental approaches, particularly increasing time outdoors, remain a critical public health strategy, particularly for delaying myopia onset.
- Emerging modalities, like colored light and surgical approaches, warrant careful investigation.
- A lifelong, proactive management mindset is essential, as myopia can progress even in adulthood.
The full white paper and concise clinical summary is freely accessible here.
